It explains the State Farm agent experience with a flow chart of agent progression through the program, and includes agent testimonials. The brochure does not include any test questions, but the website may be used to find local agents who may be willing to share some tips.
The secondary objectives are safety profile and the response rate. Lapatinib, an oral inhibitor of EGFR and HER2, have been shown to be an effective treatment in HER2/neu overexpressing metastatic breast cancer patient who refractory herceptin, taxane, and anthracycline treatment.
Lapatinib is a human epidermal growth factor receptor 2 (HER2) tyrosine kinase inhibitor (TKI) that has clinical activity in HER2-amplified breast cancer. In vitro studies have shown that lapatinib enhances the effects of the monoclonal antibody trastuzumab suggesting partially non-overlapping mechanisms of action.apatinib, a dual tyrosine kinase inhibitor (TKI) that targets both EGFR and HER2 (Wood et al., 2004; Baselga, 2006), inhibits the growth of HER2-overexpressing breast cancer cells in culture and in tumor xenografts (Chu et al., 2005; Konecny et al., 2006).